Pallavi Mohapatra, PhD

Research Fellow
Pallavi Mohapatra
Mentor
Danwei Huangfu, PhD
Start Year
2023
Education
PhD, Institute of Life Sciences, Odisha (India)

Pallavi is originally from India, where she pursued her PhD at Institute of Life Sciences under the guidance of Dr. Rupesh Dash (2018-2023). During her PhD, she studied the biology behind development of chemoresistance in Oral Squamous Cell Carcinoma and explored the alternative therapeutic options for the same. She joined Dr. Danwei Huangfu lab in 2023 as a Postdoctoral Research Fellow. With a diverse range of expertise in cancer biology she is exploring the field of stem cell biology. Her research is focused on developing models for pancreatic neuroendocrine tumor.

Publications

CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis. Mohanty S, Mohapatra P, Shriwas O, Ansari SA, Priyadarshini M, Priyadarsini S, Rath R, Sultania M, Das Majumdar SK, Swain RK, Dash R. Oncogene. 2022 Nov;41(45):4929-4940. doi: 10.1038/s41388-022-02475-8. Epub 2022 Oct 1. [PMID: 36182968]

CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis. Mohapatra P, Mohanty S, Ansari SA, Shriwas O, Ghosh A, Rath R, Majumdar SKD, Swain RK, Raghav SK, Dash R. FASEB J. 2022 Oct;36(10):e22566. doi: 10.1096/fj.202200808RR. [PMID: 36165231]

RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway. Shriwas O, Arya R, Mohanty S, Mohapatra P, Kumar S, Rath R, Kaushik SR, Pahwa F, Murmu KC, Majumdar SKD, Muduly DK, Dixit A, Prasad P, Nanda RK, Dash R. Br J Cancer. 2021 Jun;124(12):2004-2016. doi: 10.1038/s41416-021-01336-7. Epub 2021 Mar 24. [PMID: 33762722]

The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy. Shriwas O, Mohapatra P, Mohanty S, Dash R. Front Oncol. 2021 Feb 25;10:612337. doi: 10.3389/fonc.2020.612337. eCollection 2020. [PMID: 33718113]

CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis. Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, Arya R, Rath R, Das Majumdar SK, Muduly DK, Raghav SK, Nanda RK, Dash R. JCI Insight. 2021 Feb 22;6(4):e143643. doi: 10.1172/jci.insight.143643. [PMID: 33434185]